High blood pressure, or hypertension, happens when the force of blood in the arteries stays high over time. It can lead to ...

The Dermatology Devices market is expected to grow at a compound annual growth rate (CAGR) of 6.5% over the forecast period, ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

US FDA accepts Bristol Myers Squibb’s sNDA for Sotyktu to treat adults with active psoriatic arthritis: Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] Bristol Mye ...

Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between ...

The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for deucravacitinib for the treatment of adults with active psoriatic arthritis (PsA).

LP usually appears as small purple or red irritated bumps on the scalp and in some cases, it can cause hair loss. On other ...

China: A recent Mendelian randomization (MR) study has revealed that psoriasis may be inversely associated with uterine ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

Oruka Therapeutics Inc (NASDAQ:ORKA) saw its stock rise 6.6% after revealing that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application to begin a ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.